The European Hematology Association is hosting its conference in Stockholm, Sweden this week, so watch for updates from on the Myeloma Crowd site.
One update is being presented from Takeda Oncology on their INSIGHT study to better understand how myeloma treatments are being administered in the clinic. There is no standard therapy in the management of newly diagnosed or relapsed multiple myeloma, so the study wants to review real-world data versus controlled clinical trials.
Notably, the real-world data showed shorter treatment durations, progression-free and overall survival, which means that patients are not getting the therapy that is needed to keep the myeloma in check.
The INSIGHT study is the largest global observational myeloma study to date. It aims to understand patient characteristics, treatment and clinical outcomes, the link between treatment and 1) effectiveness 2) quality of life and 3) healthcare resource ultization.
More than 4,000 patients with myeloma will be enrolled from 15 countries in Europe, the United States, Latin America and Asia and followed for more than 5 years.
For this update, 1,000 patients had been enrolled in 13 countries:
Median age for newly diagnosed patients was 63. Median age for relapsed/refractory patients was 67.
The authors conclude by saying that there is no global treatment standard for newly diagnosed or relapsed refractory multiple myeloma. This is potentially due to drug and clinical trial availability and treatment patterns at academic vs. community centers.
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.